Spago Nanomedical AB (publ) (STO:SPAGO)
Sweden · Delayed Price · Currency is SEK 0.1100
-0.0025 (-2.22%)
Sep 4, 2026, 1:41 PM CET
Spago Nanomedical AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 0.04 | 0.44 | 1.91 | 1.2 | 1.05 | 0.66 |
Other Revenue | 3.77 | 4.03 | 4.74 | 4.44 | 1.46 | 1.57 |
| 3.81 | 4.47 | 6.66 | 5.64 | 2.51 | 2.23 | |
Revenue Growth | -38.05% | -32.85% | 17.95% | 124.87% | 12.61% | 60.29% |
Cost of Revenue | 12.24 | 11.48 | 14.27 | 24.49 | 20.35 | 21.69 |
Gross Profit | -8.43 | -7.01 | -7.61 | -18.84 | -17.84 | -19.46 |
Selling, General & Admin | 18.34 | 19.65 | 25.71 | 23.67 | 24.84 | 23.53 |
Other Operating Expenses | -0.57 | -0.35 | -0.26 | -0.29 | -3.95 | -4.3 |
Operating Expenses | 17.84 | 19.47 | 25.77 | 23.66 | 21.24 | 19.6 |
Operating Income | -26.27 | -26.48 | -33.38 | -42.51 | -39.09 | -39.07 |
Interest & Investment Income | 0.45 | 0.39 | 1.2 | 0.85 | 0.27 | 0.12 |
Currency Exchange Gain (Loss) | -0.32 | -0.32 | -0.33 | -0.57 | -0.38 | -0.13 |
Other Non Operating Income (Expenses) | 0 | - | - | - | - | 0 |
EBT Excluding Unusual Items | -26.14 | -26.41 | -32.51 | -42.22 | -39.2 | -39.07 |
Gain (Loss) on Sale of Assets | -0.15 | -0.15 | - | - | - | - |
Pretax Income | -26.28 | -26.55 | -32.51 | -42.22 | -39.2 | -39.07 |
Earnings From Continuing Operations | -26.28 | -26.55 | -32.51 | -42.22 | -39.2 | -39.07 |
Net Income | -26.28 | -26.55 | -32.51 | -42.22 | -39.2 | -39.07 |
Net Income to Common | -26.28 | -26.55 | -32.51 | -42.22 | -39.2 | -39.07 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 532 | 375 | 295 | 98 | 64 | 39 |
Shares Outstanding (Diluted) | 532 | 375 | 349 | 98 | 64 | 39 |
Shares Change | 52.69% | 7.25% | 256.70% | 52.68% | 62.83% | 45.01% |
EPS (Basic) | -0.05 | -0.07 | -0.11 | -0.43 | -0.61 | -0.99 |
EPS (Diluted) | -0.05 | -0.07 | -0.11 | -0.43 | -0.61 | -0.99 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -25.12 | -28.3 | -34.67 | -45.06 | -38.32 | -35.94 |
Free Cash Flow Per Share | -0.05 | -0.07 | -0.10 | -0.46 | -0.60 | -0.91 |
Gross Margin | -221.30% | -156.90% | -114.41% | - | - | - |
Operating Margin | -689.89% | -592.50% | -501.56% | -753.37% | -1557.79% | -1753.46% |
Profit Margin | -690.21% | -594.18% | -488.49% | -748.37% | -1562.26% | -1753.64% |
Free Cash Flow Margin | -659.53% | -633.18% | -520.95% | -798.69% | -1527.34% | -1613.20% |
EBITDA | -26.19 | -26.31 | -33.07 | -42.22 | -38.73 | -38.69 |
D&A For EBITDA | 0.08 | 0.17 | 0.31 | 0.28 | 0.36 | 0.38 |
EBIT | -26.27 | -26.48 | -33.38 | -42.51 | -39.09 | -39.07 |
Revenue as Reported | 4.16 | 4.82 | 6.91 | 5.93 | 6.46 | 6.53 |